Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in BRIDGEWATER, N.J., Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 3:00 p.m. PT/6:00 p.m. ET.
新澤西州布里奇沃特，2025年1月2日 /PRNewswire/ -- Insmed控股公司（納斯達克：INSM）是一家以人爲本的全球生物製藥公司，致力於提供一流及最佳的療法，以改變面臨嚴重疾病的患者的生活。今天公司宣佈管理層將於2025年1月13日星期一下午3:00（太平洋時間）/下午6:00（東部時間）在舊金山舉行的第43屆摩根大通醫療健康年會中進行演講。
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at . Webcasts will be archived for a period of 30 days following the conclusion of the live events.
本次活動將進行現場直播，您可以訪問公司網站的投資者關係部分來收看。網絡直播將在現場活動結束後保存30天。
About Insmed
關於Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Insmed控股公司是一家以人爲本的全球生物製藥公司，致力於提供一流及最佳的療法，以改變面臨嚴重疾病的患者的生活。公司正在推進多樣化的已批准和中後期的研究藥物組合，以及專注於服務患者群體的尖端藥物發現，其需求最爲迫切。Insmed最先進的項目集中在肺部和炎症疾病上，包括在美國、歐洲和日本獲得批准用於治療一種慢性、削弱生活的肺病的療法。公司的早期研究項目涵蓋廣泛的技術和模式，包括基因治療、人工智能驅動的蛋白質工程、蛋白質製造、RNA末端拼接以及合成救助。
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit to learn more.
Insmed總部位於新澤西州布里奇沃特，在美國、歐洲和日本設有辦事處和研究機構。Insmed自豪地被認定爲生物製藥行業最佳僱主之一，包括連續四年被評爲科學領域最佳僱主第一名。訪問 以了解更多信息。
Contact:
聯繫：
Investors:
投資者：
Bryan Dunn
Executive Director, Investor Relations
(646) 812-4030
[email protected]
布萊恩·鄧恩
執行董事，投資者關係
(646) 812-4030
[email protected]
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
[email protected]
邁克爾·V·莫拉比託，博士。
投資者關係董事
(917) 936-8430
[email protected]
Gianna De Palma
Manager, Investor Relations
(973) 886-2236
[email protected]
吉安納·德·帕爾瑪
投資者關係經理
(973) 886-2236
[email protected]
Media:
媒體：
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
[email protected]
曼迪·法赫
企業通信副總裁
(732) 718-3621
[email protected]
SOURCE Insmed Incorporated
Insmed Incorporated
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎？
譯文內容由第三人軟體翻譯。
